Contracts › 75N93025C00039
75N93025C00039: Is to Develop Pan-Influenza Inhibitors Targeting the Pa Endonuclease From the Viral Replication Complex By Demonstrating Pyronaridine As a Viable Single Dose Treatment for Ebola Infection in Non-Human Primates to Justify Further in Vivo Studies for U
Awarded to Collaborations Pharmaceuticals, Inc. by National Institutes of Health (NIH).
$2.0Mobligated
$2.0Mpotential value
29 December 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93025C00039 |
|---|---|
| Awardee | Collaborations Pharmaceuticals, Inc. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | NC |
| Offers received | 4 |
| Period of performance | 29 September 2025 to 29 December 2026 |
| Potential end | 29 December 2026 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record